Changing the endocrine dependence of breast cancer

Data and hypotheses

A. Nicolini, P. Ferrari, P. M. Biava, A. Carpi

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Among the most common human cancers, often only breast and prostate cancers have advantage of hormone dependence. For a long time, this advantage permitted breast cancer to be efficaciously managed in the adjuvant and metastatic settings with low side effects by endocrine therapy. Unfortunately, soon or afterward hormone dependence is lost in most patients. In breast cancer, de novo or acquired hormone resistance is an hot issue and the focus of endless debate. Although a lack of oestrogen receptors (ERs) is considered to be the main reason for de novo hormone resistance, many studies have been conducted and many different mechanisms have been hypothesised to account for acquired hormone resistance. Thus far, hormone resistance appears to be occasionally delayed or avoided in "in vivo" experiments. However, this finding did not have a significant benefit in current clinical practice. The principal aim of this review article is to sum up and update the issue of changing the endocrine dependence of breast cancer. Recent molecular insights extensively elucidating and shedding new light on this very controversial issue are considered. Moreover, based on our recent reports, a new mechanistic interpretation of and a therapeutic approach for overcome hormone resistance are proposed.

Original languageEnglish
Pages (from-to)1093-1106
Number of pages14
JournalCurrent Medicinal Chemistry
Volume21
Issue number9
DOIs
Publication statusPublished - 2014

Fingerprint

Hormones
Breast Neoplasms
Estrogen Receptors
Prostatic Neoplasms
Therapeutics
Neoplasms
Experiments

Keywords

  • Breast cancer
  • Cross-talk
  • Hormone resistance
  • Hormone responsive
  • Oestrogen receptor
  • Oestrogen receptor phosphorylation
  • Progesterone receptor

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology

Cite this

Changing the endocrine dependence of breast cancer : Data and hypotheses. / Nicolini, A.; Ferrari, P.; Biava, P. M.; Carpi, A.

In: Current Medicinal Chemistry, Vol. 21, No. 9, 2014, p. 1093-1106.

Research output: Contribution to journalArticle

Nicolini, A. ; Ferrari, P. ; Biava, P. M. ; Carpi, A. / Changing the endocrine dependence of breast cancer : Data and hypotheses. In: Current Medicinal Chemistry. 2014 ; Vol. 21, No. 9. pp. 1093-1106.
@article{eeca8c8d0eba463e8178f162a0641780,
title = "Changing the endocrine dependence of breast cancer: Data and hypotheses",
abstract = "Among the most common human cancers, often only breast and prostate cancers have advantage of hormone dependence. For a long time, this advantage permitted breast cancer to be efficaciously managed in the adjuvant and metastatic settings with low side effects by endocrine therapy. Unfortunately, soon or afterward hormone dependence is lost in most patients. In breast cancer, de novo or acquired hormone resistance is an hot issue and the focus of endless debate. Although a lack of oestrogen receptors (ERs) is considered to be the main reason for de novo hormone resistance, many studies have been conducted and many different mechanisms have been hypothesised to account for acquired hormone resistance. Thus far, hormone resistance appears to be occasionally delayed or avoided in {"}in vivo{"} experiments. However, this finding did not have a significant benefit in current clinical practice. The principal aim of this review article is to sum up and update the issue of changing the endocrine dependence of breast cancer. Recent molecular insights extensively elucidating and shedding new light on this very controversial issue are considered. Moreover, based on our recent reports, a new mechanistic interpretation of and a therapeutic approach for overcome hormone resistance are proposed.",
keywords = "Breast cancer, Cross-talk, Hormone resistance, Hormone responsive, Oestrogen receptor, Oestrogen receptor phosphorylation, Progesterone receptor",
author = "A. Nicolini and P. Ferrari and Biava, {P. M.} and A. Carpi",
year = "2014",
doi = "10.2174/0929867321666131201141741",
language = "English",
volume = "21",
pages = "1093--1106",
journal = "Current Medicinal Chemistry",
issn = "0929-8673",
publisher = "Bentham Science Publishers B.V.",
number = "9",

}

TY - JOUR

T1 - Changing the endocrine dependence of breast cancer

T2 - Data and hypotheses

AU - Nicolini, A.

AU - Ferrari, P.

AU - Biava, P. M.

AU - Carpi, A.

PY - 2014

Y1 - 2014

N2 - Among the most common human cancers, often only breast and prostate cancers have advantage of hormone dependence. For a long time, this advantage permitted breast cancer to be efficaciously managed in the adjuvant and metastatic settings with low side effects by endocrine therapy. Unfortunately, soon or afterward hormone dependence is lost in most patients. In breast cancer, de novo or acquired hormone resistance is an hot issue and the focus of endless debate. Although a lack of oestrogen receptors (ERs) is considered to be the main reason for de novo hormone resistance, many studies have been conducted and many different mechanisms have been hypothesised to account for acquired hormone resistance. Thus far, hormone resistance appears to be occasionally delayed or avoided in "in vivo" experiments. However, this finding did not have a significant benefit in current clinical practice. The principal aim of this review article is to sum up and update the issue of changing the endocrine dependence of breast cancer. Recent molecular insights extensively elucidating and shedding new light on this very controversial issue are considered. Moreover, based on our recent reports, a new mechanistic interpretation of and a therapeutic approach for overcome hormone resistance are proposed.

AB - Among the most common human cancers, often only breast and prostate cancers have advantage of hormone dependence. For a long time, this advantage permitted breast cancer to be efficaciously managed in the adjuvant and metastatic settings with low side effects by endocrine therapy. Unfortunately, soon or afterward hormone dependence is lost in most patients. In breast cancer, de novo or acquired hormone resistance is an hot issue and the focus of endless debate. Although a lack of oestrogen receptors (ERs) is considered to be the main reason for de novo hormone resistance, many studies have been conducted and many different mechanisms have been hypothesised to account for acquired hormone resistance. Thus far, hormone resistance appears to be occasionally delayed or avoided in "in vivo" experiments. However, this finding did not have a significant benefit in current clinical practice. The principal aim of this review article is to sum up and update the issue of changing the endocrine dependence of breast cancer. Recent molecular insights extensively elucidating and shedding new light on this very controversial issue are considered. Moreover, based on our recent reports, a new mechanistic interpretation of and a therapeutic approach for overcome hormone resistance are proposed.

KW - Breast cancer

KW - Cross-talk

KW - Hormone resistance

KW - Hormone responsive

KW - Oestrogen receptor

KW - Oestrogen receptor phosphorylation

KW - Progesterone receptor

UR - http://www.scopus.com/inward/record.url?scp=84896327395&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896327395&partnerID=8YFLogxK

U2 - 10.2174/0929867321666131201141741

DO - 10.2174/0929867321666131201141741

M3 - Article

VL - 21

SP - 1093

EP - 1106

JO - Current Medicinal Chemistry

JF - Current Medicinal Chemistry

SN - 0929-8673

IS - 9

ER -